Thymalin
- Category
- Immune & Defense
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A thymic peptide extract marketed to restore immune function and normalize T-cell balance in aging adults. Evidence is low confidence throughout: claims of reduced mortality, extended lifespan, and better severe COVID-19 outcomes rest on small, older, or animal studies, not robust human trials. Western safety data is limited and most supply is unregulated research-grade product of uncertain purity. Not an approved drug in the US.
Read Full recordStudied uses & evidence
Studied uses(6)
Reduction of all-cause mortality in elderly patients via immune restoration
LowBased on one unblinded, non-randomized human cohort study, never independently replicated.
Stimulation of hematopoietic stem cell differentiation into mature T-lymphocytes
LowDemonstrated in one human cell-culture study only, with no in vivo confirmation yet.
Extended lifespan and reduced spontaneous carcinogenesis in animal models
LowConsistent rodent data from one research group, with modest effects on average lifespan.
Evidence limits
- Evidence Level
- Moderate
Thymalin has a more substantial clinical evidence base than most Khavinson bioregulators, owing to its pharmaceutical status in Russia since 1982 and the 40+ years of clinical application. The strongest evidence comes from the 266-patient elderly longevity study demonstrating 2.0-2.1-fold mortality reduction over 6-8 years (and 4.1-fold with combined annual treatment), and the COVID-19 study showing halved hospital mortality in severe elderly patients receiving Thymalin as adjunctive therapy. The listed rat and CBA-mouse lifespan studies tested synthetic peptides rather than Thymalin extract. The Glu-Trp rat study found similar mean lifespan, although the longest-lived animals survived longer and tumor incidence decreased. Mechanistic evidence is well-characterized: Thymalin stimulates hematopoietic stem cell differentiation into mature T-lymphocytes (6.8-fold CD28 increase), activates T-cell immunity, and regulates gene expression through direct DNA binding. Major limitations: the human longevity study was not an RCT, all research originates from Khavinson-affiliated groups, no independent Western replication exists, and no FDA-standard clinical trials have been conducted.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Organ transplant recipients
HighThymic peptide immune stimulation may counteract immunosuppressive therapy.
Active autoimmune disease
ModerateImmune modulation via thymic peptides may exacerbate autoimmune conditions.
General cautions
Pregnancy
AbsoluteNo reproductive safety data.
Risk summary(7)
Risks = level of concern: High · Moderate · Low · Theoretical
Potential interference with immunosuppressive therapy
TheoreticalLimited Western safety data and lack of independent validation
HighTheoretical risk of immune overstimulation or autoimmunity
TheoreticalCaution with active thymic tumors or thymoma
TheoreticalUnregulated product quality from research-grade sources
HighContraindicated in pregnancy, lactation, and specific populations
ModerateMild injection site reactions
Low
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.